MWP
GALT icon

MYCIO Wealth Partners’s Galectin Therapeutics GALT Stock Holding History

MYCIO Wealth Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,000
Closed -$16K – 632
2013
Q4 		$16K Hold
2,000
– – ﹤0.01% 394
2013
Q3 		$20K Buy
+2,000
New +$13.5K 0.01% 329

Other funds holding GALT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

MYCIO Wealth Partners's GALT Position: Q1 2014 in Review

MYCIO Wealth Partners sold out of Galectin Therapeutics (GALT) in Q1 2014, closing a stake of 2,000 shares — an estimated $16K sold.

MYCIO Wealth Partners first reported a position in GALT in Q3 2013 and held it in 2 quarters. The position peaked at $20K in Q3 2013. 55 funds tracked by Wall St. Rank hold GALT as of Q1 2014.

  • MYCIO Wealth Partners reported no remaining Galectin Therapeutics position as of Q1 2014 after selling out during the quarter.
  • MYCIO Wealth Partners sold 2,000 Galectin Therapeutics shares in Q1 2014, an estimated $16K.
  • MYCIO Wealth Partners first reported a position in Galectin Therapeutics in Q3 2013 and held it in 2 quarters.
  • MYCIO Wealth Partners's Galectin Therapeutics position peaked at $20K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2014.

Based on MYCIO Wealth Partners's 13F filing for Q1 2014, filed 13 May 2014.